CYTOPHAGE TECHNOLOGIES LTD (CYTO.CA) Stock Fundamental Analysis
Canada - TSX Venture Exchange - TSX-V:CYTO - CA2328211081 - Common Stock
0.145 CAD
-0.03 (-14.71%)
Taking everything into account, CYTO scores 0 out of 10 in our fundamental rating. CYTO was compared to 0 industry peers in the Unkown industry. CYTO may be in some trouble as it scores bad on both profitability and health. CYTO is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- CYTO had negative earnings in the past year.
- CYTO had a negative operating cash flow in the past year.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -143.59% | ||
| ROE | -391.47% | ||
| ROIC | N/A |
ROA(3y)-114.73%
ROA(5y)N/A
ROE(3y)-539.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for CYTO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- CYTO has more shares outstanding than it did 1 year ago.
- Compared to 1 year ago, CYTO has an improved debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of -12.49, we must say that CYTO is in the distress zone and has some risk of bankruptcy.
- CYTO has a Debt/Equity ratio of 0.98. This is a neutral value indicating CYTO is somewhat dependend on debt financing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.98 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -12.49 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- CYTO has a Current Ratio of 0.66. This is a bad value and indicates that CYTO is not financially healthy enough and could expect problems in meeting its short term obligations.
- A Quick Ratio of 0.66 indicates that CYTO may have some problems paying its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.66 | ||
| Quick Ratio | 0.66 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 71.14% over the past year.
EPS 1Y (TTM)71.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- CYTO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for CYTO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CYTOPHAGE TECHNOLOGIES LTD / CYTO.CA FAQ
What is the fundamental rating for CYTO stock?
ChartMill assigns a fundamental rating of 0 / 10 to CYTO.CA.
Can you provide the valuation status for CYTOPHAGE TECHNOLOGIES LTD?
ChartMill assigns a valuation rating of 0 / 10 to CYTOPHAGE TECHNOLOGIES LTD (CYTO.CA). This can be considered as Overvalued.
What is the profitability of CYTO stock?
CYTOPHAGE TECHNOLOGIES LTD (CYTO.CA) has a profitability rating of 0 / 10.
How financially healthy is CYTOPHAGE TECHNOLOGIES LTD?
The financial health rating of CYTOPHAGE TECHNOLOGIES LTD (CYTO.CA) is 1 / 10.